AKBA Q4 2023 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M+1.8% YoY

Gross Profit

$38M66.8% margin

Operating Income

$1M2.4% margin

Net Income

$614,0001.1% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

+33.7%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$242M

Total Liabilities

$272M

Stockholders' Equity

-$31M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$55M	+1.8%
Gross Profit	$38M	$58M	-35.6%
Operating Income	$1M	-$6M	+121.6%
Net Income	$614,000	-$8M	+108.1%

Revenue Segments

Product

$93M95%

License Collaboration And Other Revenue

$5M5%